ABUS
Arbutus Biopharma
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Arbutus launched international patent infringement actions against Pfizer and BioNTech, received the first Moderna settlement payment, and announced plans to return capital to shareholdersJul 16, 2026
- Arbutus received FDA Fast Track designation for imdusiran for chronic hepatitis BApr 15, 2026
- Arbutus presents clinical trial data from its two HBV assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025.May 7, 2025